Genetics, genomics and proteomics
.png "Katherine Liao, MD, MPH photo")
Katherine Liao, MD, MPH
Brigham and Women's Hospital
Boston, MA, United States
Disclosure(s): UCB: Consultant (Terminated, October 5, 2022)
.png "Yukinori Okada, MD, PhD photo")
Yukinori Okada, MD, PhD
The University of Tokyo / Osaka University / RIKEN
Tokyo, Japan
Disclosure(s): No financial relationships with ineligible companies to disclose
This session will provide attendees with the latest and cutting-edge updates of trans-omics and translational research activities in rheumatology. Recent advances in high-throughput omics technologies, such as large-scale human genomics, next generation sequencing, and electrical medical records (EMR) from hospital-based biobanks, provide us a wealth of clinical information. We now face the challenge in how to leverage such multimodal omics resources in translation from molecular to clinical aspects of rheumatology. While this should shed light on elucidation of disease biology and social implementation of personalized medicine of rheumatic diseases, its practical way is not yet demonstrated. In this session, leading scientists from Japan College of Rheumatology (JCR) and American College of Rheumatology (ACR) will present their latest collaborative overviews: How the integrative analysis of multi-modal trans-omics technologies can tell us biology of rheumatic diseases and translation to bedside? Professor Okada presents the latest overview in what we have learned from human genomics to understand rheumatology. Dr. Liao introduces how to leverage machine learning-based EMR and genomics from hospital-based biobank resources for personalized medicine in rheumatology. This session also aims to consolidate academic and clinical collaboration network between ACR and JCR
Speaker: Yukinori Okada, MD, PhD – The University of Tokyo / Osaka University / RIKEN
Speaker: Katherine Liao, MD, MPH – Brigham and Women's Hospital
